3,000 Shares in AVITA Medical, Inc. (NASDAQ:RCEL) Purchased by Huntington National Bank

Huntington National Bank purchased a new position in AVITA Medical, Inc. (NASDAQ:RCEL) during the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 3,000 shares of the company’s stock, valued at approximately $32,000.

A number of other institutional investors also recently bought and sold shares of RCEL. Silvercrest Asset Management Group LLC purchased a new position in shares of AVITA Medical during the 1st quarter valued at about $3,874,000. Essex Investment Management Co. LLC acquired a new stake in AVITA Medical during the third quarter worth about $2,477,000. Vanguard Group Inc. raised its position in AVITA Medical by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,408,136 shares of the company’s stock valued at $22,572,000 after acquiring an additional 15,356 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in AVITA Medical in the second quarter valued at approximately $86,000. Finally, Rhumbline Advisers boosted its position in AVITA Medical by 13.9% in the 2nd quarter. Rhumbline Advisers now owns 36,530 shares of the company’s stock worth $289,000 after purchasing an additional 4,463 shares in the last quarter. 27.66% of the stock is owned by hedge funds and other institutional investors.

AVITA Medical Stock Up 4.3 %

AVITA Medical stock opened at $12.96 on Wednesday. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.73 and a quick ratio of 3.37. The stock has a market capitalization of $339.81 million, a PE ratio of -5.81 and a beta of 1.54. The business has a 50 day simple moving average of $10.85 and a 200-day simple moving average of $9.56. AVITA Medical, Inc. has a 12 month low of $7.51 and a 12 month high of $18.93.

AVITA Medical (NASDAQ:RCEL) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.21). AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.47%. The company had revenue of $19.55 million for the quarter, compared to analyst estimates of $19.65 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. On average, analysts anticipate that AVITA Medical, Inc. will post -2.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Piper Sandler reiterated a “neutral” rating and issued a $12.00 target price (up from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of AVITA Medical in a research report on Friday, August 9th.

AVITA Medical Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.